去年秋天,美国宾夕法尼亚大学采用基因疗法治疗,导致1例18岁鸟氨酸-胞嘧啶转移酶(OCT)缺乏症病人的死亡。美国FDA最近又否决了宾夕法尼亚大学就此事所做的辩解。根据调查。FDA停止了宾夕法尼亚大学基因治疗研究所的基因治疗试验。在这些实验中,复制缺陷的腺病毒作为载体将治疗 Last fall, treatment with gene therapy at the University of Pennsylvania led to the death of one 18-year-old ornithine-cytosine transferase (OCT) -deficient patient. The U.S. FDA recently rejected the claim made by the University of Pennsylvania on the matter. According to the survey. The FDA stopped the gene therapy trial at the Institute for Gene Therapy at the University of Pennsylvania. In these experiments, replication-deficient adenovirus was treated as a vector